The Boston-based biotech Jnana Therapeutics just announced its launch with a US$ 50m Series A financing. Its focus will be to build the first discovery platform dedicated to targeting the solute carrier (SLC) family of transporters. The SLC transporters is a family of more than 300 membrane-bound proteins that facilitate the transport of a wide array of substrates across biological membranes. The SLC transporters have important roles in physiological processes, ranging from t